Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison.

Alzheimer Disease / diagnostic imaging Amyloid Amyloid beta-Peptides Amyloidosis Cognitive Dysfunction Humans Positron-Emission Tomography tau Proteins
Amyloid Florbetapir Flortaucipir Flutemetamol PET Tau

Journal

European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988

Informations de publication

Date de publication:
07 2021
Historique:
received: 28 10 2020
accepted: 07 02 2021
pubmed: 28 2 2021
medline: 29 6 2021
entrez: 27 2 2021
Statut: ppublish

Résumé

Assess the individual and combined diagnostic value of amyloid-PET and tau-PET in a memory clinic population. Clinical reports of 136 patients were randomly assigned to two diagnostic pathways: AMY-TAU, amyloid-PET is presented before tau-PET; and TAU-AMY, tau-PET is presented before amyloid-PET. Two neurologists independently assessed all reports with a balanced randomized design, and expressed etiological diagnosis and diagnostic confidence (50-100%) three times: (i) at baseline based on the routine diagnostic workup, (ii) after the first exam (amyloid-PET for the AMY-TAU pathway, and tau-PET for the TAU-AMY pathway), and (iii) after the remaining exam. The main outcomes were changes in diagnosis (from AD to non-AD or vice versa) and in diagnostic confidence. Amyloid-PET and tau-PET, when presented as the first exam, resulted in a change of etiological diagnosis in 28% (p = 0.006) and 28% (p < 0.001) of cases, and diagnostic confidence increased by 18% (p < 0.001) and 19% (p < 0.001) respectively, with no differences between exams (p > 0.05). We observed a stronger impact of a negative amyloid-PET versus a negative tau-PET (p = 0.014). When added as the second exam, amyloid-PET and tau-PET resulted in a further change in etiological diagnosis in 6% (p = 0.077) and 9% (p = 0.149) of cases, and diagnostic confidence increased by 4% (p < 0.001) and 5% (p < 0.001) respectively, with no differences between exams (p > 0.05). Amyloid-PET and tau-PET significantly impacted diagnosis and diagnostic confidence in a similar way, although a negative amyloid-PET has a stronger impact on diagnosis than a negative tau-PET. Adding either of the two as second exam further improved diagnostic confidence. PB 2016-01346.

Identifiants

DOI: 10.1007/s00259-021-05246-x PMID: 33638661 PMC: PMC8175315
pubmed: 33638661
doi: 10.1007/s00259-021-05246-x
pii: 10.1007/s00259-021-05246-x
pmc: PMC8175315
doi:

Substances chimiques

Amyloid 0
Amyloid beta-Peptides 0
tau Proteins 0

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2200-2211

Subventions

Organisme : EU-EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (IMI 2 JU)
ID : 115952
Organisme : Swiss National Science Foundation
ID : 320030_169876
Pays : Switzerland
Organisme : Swiss National Science Foundation
ID : 320030_185028
Pays : Switzerland

Références

Villemagne VL, Doré V, Burnham SC, Masters CL, Rowe CC. Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions. Nat Rev Neurol. 2018;14:225–36. https://doi.org/10.1038/nrneurol.2018.9 .
doi: 10.1038/nrneurol.2018.9 pubmed: 29449700
Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12:292–323. https://doi.org/10.1016/j.jalz.2016.02.002 .
doi: 10.1016/j.jalz.2016.02.002 pubmed: 27012484 pmcid: 6417794
Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14:535–62. https://doi.org/10.1016/j.jalz.2018.02.018 .
doi: 10.1016/j.jalz.2018.02.018 pubmed: 29653606 pmcid: 5958625
Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B. Ann Neurol. 2004;55:306–19. https://doi.org/10.1002/ana.20009 .
doi: 10.1002/ana.20009 pubmed: 14991808
Barthel H, Sabri O. Clinical use and utility of amyloid imaging. J Nucl Med. 2017;58:1711–7. https://doi.org/10.2967/jnumed.116.185017 .
doi: 10.2967/jnumed.116.185017 pubmed: 28818990
Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34:457–68. https://doi.org/10.3233/JAD-122059 .
doi: 10.3233/JAD-122059 pubmed: 23234879
Wolters EE, A. Dodich A, Boccardi M, Corre j, Drzezga A, Hansson O et al. Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-020-05118-w
FDA Approves First Drug to Image Tau Pathology in Patients Being Evaluated for Alzheimer’s Disease | FDA n.d. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-image-tau-pathology-patients-being-evaluated-alzheimers-disease (accessed September 7, 2020).
Ramusino MC, Garibotto V, Bacchin R, Altomare D, Dodich A, Assal F, et al. Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2020;47:270–80. https://doi.org/10.1007/s00259-019-04466-6 .
doi: 10.1007/s00259-019-04466-6 pubmed: 31388720
Jessen F, Amariglio RE, Buckley RF, van der Flier WM, Han Y, Molinuevo JL, et al. The characterisation of subjective cognitive decline. Lancet Neurol. 2020;19:271–8. https://doi.org/10.1016/S1474-4422(19)30368-0 .
doi: 10.1016/S1474-4422(19)30368-0 pubmed: 31958406 pmcid: 7062546
Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:270–9. https://doi.org/10.1016/j.jalz.2011.03.008 .
doi: 10.1016/j.jalz.2011.03.008 pubmed: 21514249 pmcid: 3312027
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9. https://doi.org/10.1016/j.jalz.2011.03.005 .
doi: 10.1016/j.jalz.2011.03.005 pubmed: 21514250 pmcid: 3312024
Chui HC, Mack W, Jackson JE, Mungas D, Reed BR, Tinklenberg J, et al. Clinical criteria for the diagnosis of vascular dementia: a multicenter study of comparability and interrater reliability. Arch Neurol. 2000;57:191–6. https://doi.org/10.1001/archneur.57.2.191 .
doi: 10.1001/archneur.57.2.191 pubmed: 10681076
Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies: report of the ninds-airen international workshop*. Neurology. 1993;43:250–60. https://doi.org/10.1212/wnl.43.2.250 .
doi: 10.1212/wnl.43.2.250 pubmed: 8094895
Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, et al. Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl. 2000;59:23–30. https://doi.org/10.1007/978-3-7091-6781-6_4 .
doi: 10.1007/978-3-7091-6781-6_4 pubmed: 10961414
Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456–77. https://doi.org/10.1093/brain/awr179 .
doi: 10.1093/brain/awr179 pubmed: 21810890 pmcid: 21810890
McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology. 2005;65:1863–72. https://doi.org/10.1212/01.wnl.0000187889.17253.b1 .
doi: 10.1212/01.wnl.0000187889.17253.b1 pubmed: 16237129
Jack CR, Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V, et al. An operational approach to National Institute on Aging-Alzheimer’s Association criteria for preclinical Alzheimer disease. Ann Neurol. 2012;71:765–75. https://doi.org/10.1002/ana.22628 .
doi: 10.1002/ana.22628 pubmed: 22488240 pmcid: 3586223
Jack CR, Knopman DS, Chételat G, Dickson D, Fagan AM, Frisoni GB, et al. Suspected non-Alzheimer disease pathophysiology-concept and controversy. Nat Rev Neurol. 2016;12:117–24. https://doi.org/10.1038/nrneurol.2015.251 .
doi: 10.1038/nrneurol.2015.251 pubmed: 26782335 pmcid: 4784257
Shcherbinin S, Schwarz AJ, Joshi A, Navitsky M, Flitter M, Shankle WR, et al. Kinetics of the tau PET tracer 18F-AV-1451 (T807) in subjects with normal cognitive function, mild cognitive impairment, and Alzheimer disease. J Nucl Med. 2016;57:1535–42. https://doi.org/10.2967/jnumed.115.170027 .
doi: 10.2967/jnumed.115.170027 pubmed: 27151986
Vizamyl - European Medicines Agency - Summary of Product Characteristics n.d. https://www.ema.europa.eu/en/documents/product-information/vizamyl-epar-product-information_en.pdf (accessed October 13, 2020).
Amyvid - European Medicines Agency - Summary of Product Characteristics n.d. https://www.ema.europa.eu/en/documents/product-information/amyvid-epar-product-information_en.pdf (accessed October 13, 2020).
Fleisher AS, Pontecorvo MJ, Devous MD, Lu M, Arora AK, Truocchio SP, et al. Positron emission tomography imaging with [18F] flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes. JAMA Neurol. 2020. https://doi.org/10.1001/jamaneurol.2020.0528 .
Dodich A, Rochat A-S, Mainta I, Noirot C, Andryszak P, Rakotomiaramanana B, et al. Validation of a visual assessment strategy for 18F-Flortaucipir PET. EANM. 2019;19.
Gold G, Bouras C, Kövari E, Canuto A, Glaría BG, Malky A, et al. Clinical validity of Braak neuropathological staging in the oldest-old. Acta Neuropathol. 2000;99:579–82. https://doi.org/10.1007/s004010051163 .
doi: 10.1007/s004010051163 pubmed: 10805104
Lowe VJ, Lundt ES, Albertson SM, Min HK, Fang P, Przybelski SA, et al. Tau-positron emission tomography correlates with neuropathology findings. Alzheimers Dement. 2020;16:561–71. https://doi.org/10.1016/j.jalz.2019.09.079 .
doi: 10.1016/j.jalz.2019.09.079 pubmed: 31784374 pmcid: 7067654
Sonni I, Lesman Segev OH, Baker SL, Iaccarino L, Korman D, Rabinovici GD, et al. Evaluation of a visual interpretation method for tau-PET with 18 F-flortaucipir. Alzheimer’s Dement Diagnosis, Assess Dis Monit. 2020;12. https://doi.org/10.1002/dad2.12133 .
Frisoni GB, Barkhof F, Altomare D, Berkhof J, Boccardi M, Canzoneri E, et al. AMYPAD diagnostic and patient management study: rationale and design. Alzheimers Dement. 2019;15:388–99. https://doi.org/10.1016/j.jalz.2018.09.003 .
doi: 10.1016/j.jalz.2018.09.003 pubmed: 30339801
Aschenbrenner AJ, Gordon BA, Benzinger TLS, Morris JC, Hassenstab JJ. Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. Neurology. 2018;91:e859–66. https://doi.org/10.1212/WNL.0000000000006075 .
doi: 10.1212/WNL.0000000000006075 pubmed: 30068637 pmcid: 6133625
Mufson EJ, Malek-Ahmadi M, Snyder N, Ausdemore J, Chen K, Perez SE. Braak stage and trajectory of cognitive decline in noncognitively impaired elders. Neurobiol Aging. 2016;43:101–10. https://doi.org/10.1016/j.neurobiolaging.2016.03.003 .
doi: 10.1016/j.neurobiolaging.2016.03.003 pubmed: 27255819 pmcid: 4894536
Ossenkoppele R, Smith R, Ohlsson T, Strandberg O, Mattsson N, Insel PS, et al. Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease. Neurology. 2019;92:e601–12. https://doi.org/10.1212/WNL.0000000000006875 .
doi: 10.1212/WNL.0000000000006875 pubmed: 30626656 pmcid: 6382060
Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol. 2004;61:378–84. https://doi.org/10.1001/archneur.61.3.378 .
doi: 10.1001/archneur.61.3.378 pubmed: 15023815
Hammes J, Bischof G, Bohn K, Onur O, Schneider A, Fliessbach K, et al. One stop shop: flortaucipir PET differentiates amyloid positive and negative forms of neurodegenerative diseases. J Nucl Med. 2020. https://doi.org/10.2967/jnumed.120.244061 .
Xia C, Makaretz SJ, Caso C, McGinnis S, Gomperts SN, Sepulcre J, et al. Association of in vivo [18F]AV-1451 tau PET imaging results with cortical atrophy and symptoms in typical and atypical Alzheimer disease. JAMA Neurol. 2017;74:427–36. https://doi.org/10.1001/jamaneurol.2016.5755 .
doi: 10.1001/jamaneurol.2016.5755 pubmed: 28241163 pmcid: 5470368
Van Eimeren T, Bischof GN, Drzezga A. Is tau imaging more than just upside-down 18F-FDG imaging? J Nucl Med. 2017;58:1357–9. https://doi.org/10.2967/jnumed.117.190082 .
doi: 10.2967/jnumed.117.190082 pubmed: 28490468
Chiotis K, Saint-Aubert L, Rodriguez-Vieitez E, Leuzy A, Almkvist O, Savitcheva I, et al. Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer’s disease dementia. Mol Psychiatry. 2018;23:1666–73. https://doi.org/10.1038/mp.2017.108 .
doi: 10.1038/mp.2017.108 pubmed: 28507319
Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207–16. https://doi.org/10.1016/S1474-4422(12)70291-0 .
doi: 10.1016/S1474-4422(12)70291-0 pubmed: 23332364 pmcid: 3622225
Tsai RM, Bejanin A, Lesman-Segev O, Lajoie R, Visani A, Bourakova V, et al. 18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. Alzheimers Res Ther. 2019;11. https://doi.org/10.1186/s13195-019-0470-7 .
Boccardi M, Dodich A, Albanese E, Gayet‐Ageron A, Walter M, Rabinovici GD, et al. The biomarker roadmap for the validation for Alzheimer’s biomarkers: Methodological update for biomarkers of tauopathy. Alzheimers Dement. 2020. https://doi.org/10.1002/alz.039063 .

Auteurs

Daniele Altomare (D)

Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland. Daniele.Altomare@unige.ch.
Memory Clinic, Geneva University Hospitals, Geneva, Switzerland. Daniele.Altomare@unige.ch.
ORCID: 0000-0003-1905-8993

Camilla Caprioglio (C)

Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland.
Memory Clinic, Geneva University Hospitals, Geneva, Switzerland.

Frédéric Assal (F)

Division of Neurology, Department of Clinical Neurosciences, Geneva University Hospitals, Geneva, Switzerland.
Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Gilles Allali (G)

Division of Neurology, Department of Clinical Neurosciences, Geneva University Hospitals, Geneva, Switzerland.
Department of Neurology, Division of Cognitive & Motor Aging, Albert Einstein College of Medicine, Yeshiva University, Bronx, NY, USA.

Aline Mendes (A)

Division of Geriatrics, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, Switzerland.

Federica Ribaldi (F)

Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland.
Laboratory of Alzheimer's Neuroimaging and Epidemiology (LANE), Saint John of God Clinical Research Centre, Brescia, Italy.
Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

Kelly Ceyzeriat (K)

Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTlab), Geneva University Neurocenter and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Division of Adult Psychiatry, Department of Psychiatry, Geneva University Hospitals, Geneva, Switzerland.

Marta Martins (M)

Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland.
Memory Clinic, Geneva University Hospitals, Geneva, Switzerland.

Szymon Tomczyk (S)

Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland.
Memory Clinic, Geneva University Hospitals, Geneva, Switzerland.

Sara Stampacchia (S)

Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTlab), Geneva University Neurocenter and Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Alessandra Dodich (A)

Center for Mind/Brain Sciences (CIMeC), University of Trento, Rovereto, Italy.

Marina Boccardi (M)

Late Translational Dementia Research Group, German Center for Neurodegenerative Diseases (DZNE), Rostock-Greifswald site, Rostock, Germany.

Christian Chicherio (C)

Memory Clinic, Geneva University Hospitals, Geneva, Switzerland.

Giovanni B Frisoni (GB)

Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland.
Memory Clinic, Geneva University Hospitals, Geneva, Switzerland.

Valentina Garibotto (V)

Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospitals, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Démence › Maladie d'Alzheimer › Diagnostic value of amyloid-PET and tau-PET: a...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Amyloïde › Diagnostic value of amyloid-PET and tau-PET: a...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Peptides bêta-amyloïdes › Diagnostic value of amyloid-PET and tau-PET: a...
questionsmedicales.fr › Maladies métaboliques et nutritionnelles › Maladies métaboliques › Troubles de l'homéostasie des protéines › Amyloïdose › Diagnostic value of amyloid-PET and tau-PET: a...
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Troubles de la cognition › Dysfonctionnement cognitif › Diagnostic value of amyloid-PET and tau-PET: a...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Diagnostic value of amyloid-PET and tau-PET: a...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Diagnostic value of amyloid-PET and tau-PET: a...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines de tissu nerveux › Protéines associées aux microtubules › Protéines tau › Diagnostic value of amyloid-PET and tau-PET: a...